Chromogenic in situ hybridization analysis of epidermal growth factor receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays

Pathology and Oncology Research

Volumn 15, Issue 3, 2009, Pages 511-520

  Tsiambas, Evangelos ^a   Manaios, Loukas ^b   Papanikolopoulos, Costas ^c   Rigopoulos, Dimitrios N ^c   Tsounis, Dimitrios ^d   Karameris, Andreas ^e   Soultati, Aspasia ^f   Koliopoulou, Antigoni ^g   Kravvaritis, Christos ^e   Sergentanis, Theodoros ^f   Patsouris, Efstratios ^f   Dourakis, Spyridon ^f  

^a NIMTS HOSPITAL   (Greece)

^b Bioclinic ^*  (Greece)

^c 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^d 251 AF Hospital   (Greece)

^e 417 VA Hospital (NIMTS)   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Chromogenic in situ hybridization; Epidermal growth factor receptor; Hepatocellular carcinoma; Tissue microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RECEPTOR PROTEIN;

ADULT; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; MALE; PROGNOSIS; RECEPTOR GENE; SURVIVAL RATE; TISSUE MICROARRAY;

CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, ERBB-1; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 73449105421     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9146-5     Document Type: Article

References (41)

1. H El Serag JA Davila NJ Petersen KA McGlynn 2003 The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 817 23 14623619
2. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 17 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
3. DS Krause RA Van Etten 2005 Tyrosine kinases as targets for cancer therapy N Engl J Med 353 172 187 10.1056/NEJMra044389 1:CAS:528: DC%2BD2MXmtFClsbs%3D 16014887 (Pubitemid 41058349)
4. J Molina A Adjei 2006 The Ras/Raf/MAPK Pathway J Thorac Oncol 1 7 9 10.1097/01243894-200601000-00004 17409820
5. A Marquez R Wu J Zhao J Tao Z Shi 2004 Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy Diagn Mol Pathol 13 1 8 10.1097/00019606-200403000-00001 1:CAS:528: DC%2BD2cXivVWjtLs%3D 15163002 (Pubitemid 38263876)
6. PM Harari 2004 Epidermal growth factor receptor inhibition strategies in oncology Endocrine-Related Cancer 11 689 708 10.1677/erc.1.00600 1:CAS:528:DC%2BD2MXhtVarsb8%3D 15613446 (Pubitemid 40065545)
7. C Arteaga 2001 The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol 19 S18 32 40
8. MW Wiedmann K Casa 2005 Molecular targeted therapy for gastrointestinal cancer Curr Cancer Drug Targets 5 171 93 10.2174/1568009053765771 1:CAS:528:DC%2BD2MXksFKktr8%3D 15892618 (Pubitemid 40694859)
9. TJ Lynch DW Bell R Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 39 10.1056/NEJMoa040938 1:CAS:528: DC%2BD2cXktF2js7c%3D 15118073 (Pubitemid 38637993)
10. JG Paez PA Janne JC Lee 2005 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 500 10.1126/science.1099314
11. SM Huang EA Armstrong S Benavente P Chinnaiyan PM Harari 2004 Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 5355 62 10.1158/0008-5472.CAN-04-0562 1:CAS:528:DC%2BD2cXmtF2murY%3D 15289342 (Pubitemid 39006556)
12. AX Zhu K Stuart LS Blaszkowsky 2007 Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 3 581 9 10.1002/cncr.22829 1:CAS:528:DC%2BD2sXpt1yqu7s%3D 17583545
13. YN Zhao J Cao FX Wu 2004 Expression and significance of EGF m-RNA and EGFR m-RNA in hepatocellular carcinoma Ai Zheng 23 762 6 1:CAS:528: DC%2BD2cXhtVymu77L 15248908
14. J Foster J Black C LeVea 2007 COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival Ann Surg Oncol. 14 2 752 8 10.1245/s10434-006-9123-8 17146741 (Pubitemid 46175323)
15. K Breuhahn T Longerich P Schirmacher 2006 Dysregulation of growth factor signaling in human hepatocellular carcinoma Oncogene 25 27 3787 0 10.1038/sj.onc.1209556 1:CAS:528:DC%2BD28XmtFCntL0%3D 16799620 (Pubitemid 43980474)
16. A Villanueva P Newell DY Chiang SL Friedman JM Llovet 2007 Genomics and signaling pathways in hepatocellular carcinoma Semin Liver Dis 27 1 55 76 10.1055/s-2006-960171 1:CAS:528:DC%2BD2sXjtlWrsLs%3D 17295177 (Pubitemid 46269805)
17. E Szabó C Páska P Kaposi Novák Z Schaff A Kiss 2004 Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis Pathol Oncol Res 10 1 5 11 10.1007/BF02893401 15029254
18. GJ Walker NK Hayward S Falvey WG Cooksley 1991 Loss of somatic heterozygosity in hepatocellular carcinoma Cancer Res 51 16 4367 70 1:STN:280:DyaK3MzjtVWmtw%3D%3D 1678314
19. F Staib SP Hussain LJ Hofseth XW Wang CC Harris 2003 TP53 and liver carcinogenesis Hum Mutat 21 3 201 16 10.1002/humu.10176 1:CAS:528: DC%2BD3sXis1yjtro%3D 12619106 (Pubitemid 36292963)
20. ME Reeves RP DeMatteo 2000 Genes and viruses in hepatobiliary neoplasia Semin Surg Oncol 19 2 84 93 10.1002/1098-2388(200009)19:2<84::AID-SSU2>3. 0.CO;2-0 1:STN:280:DC%2BD3M7gtlOitQ%3D%3D 11126384 (Pubitemid 30825548)
21. S Lee U Park YI Lee 2001 Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites Virology 283 2 167 77 10.1006/viro.2001.0892 1:CAS:528:DC%2BD3MXjt1Wgtbw%3D 11336542 (Pubitemid 32881164)
22. B Friedrich M Wollersheim B Brandenburg R Foerste H Will E Hildt 2005 Induction of anti-proliferative mechanisms in hepatitis B virus producing cells J Hepatol. 43 4 696 703 10.1016/j.jhep.2005.02.026 1:CAS:528: DC%2BD2MXpvFamtLc%3D 15922479 (Pubitemid 41253238)
23. A El-Bassiouni M Nosseir M Zoheiry E El-Ahwany A Ghali N El-Bassiouni 2006 Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma APMIS 114 6 420 7 10.1111/j.1600-0463.2006.apm-323.x 1:CAS:528:DC%2BD28XosFequ74%3D 16856963
24. SC Lee SG Lim R Soo 2007 Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma Pharmacogenet Genomics 16 1 73 4 10.1097/01.fpc.0000184959.82903.02
25. MC Su HC Lien YM Jeng 2005 Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma Cancer Lett 224 1 117 21 1:CAS:528:DC%2BD2MXks1aktr8%3D 15911107
26. T Bekaii-Saab N Williams C Plass MV Calero C Eng 2006 A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma BMC Cancer 6 278 85 10.1186/1471-2407-6-278 17150109 (Pubitemid 46019358)
27. PA Philip MR Mahoney C Allmer 2005 Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 6657 63 10.1200/JCO.2005.14.696 1:CAS:528:DC%2BD2MXhtFWqsLbJ 16170173 (Pubitemid 46190260)
28. M Höpfner AP Sutter A Huether D Schuppan M Zeitz H Scherübl 2004 Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 6 1008 16 10.1016/j.jhep.2004.08.024 15582135 (Pubitemid 39575669)
29. A Huether M Hopfner V Baradari D Schuppan H Scherubl 2005 EGFR blockade by cetuximab alone or as combination therapy fot growth control of hepatocellular cancer Biochem Pharmacol 70 11 1568 78 10.1016/j.bcp.2005.09.007 1:CAS:528:DC%2BD2MXhtFKhsL%2FJ 16226226 (Pubitemid 41540350)
30. S Ramalingam CP Belani 2007 Recent advances in targeted therapy for non-small cell lung cancer Expert Opin Ther Targets 11 2 245 57 10.1517/14728222.11.2.245 1:CAS:528:DC%2BD2sXlt12rsg%3D%3D 17227238 (Pubitemid 46188817)
31. AF Buckley LJ Burgart S Kakar 2006 Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma Hum Pathol. 37 4 410 4 10.1016/j.humpath.2005.12.009 1:CAS:528:DC%2BD28XivVGhtrw%3D 16564914
32. L Wilkens M Bredt A Flemming 2002 Detection of chromosomal aberrations in well-differentiated hepatocellular carcinoma by bright-field in situ hybridization Mod Pathol 15 4 470 5 10.1038/modpathol.3880548 11950923 (Pubitemid 34326957)
33. M Moroni S Veronese S Benvenuti 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 5 279 86 10.1016/S1470-2045(05) 70102-9 1:CAS:528:DC%2BD2MXjs1Krsb8%3D 15863375 (Pubitemid 40590264)
34. WS Moon KJ Chang AP Majumdar AS Tarnawski 2004 Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth Digestion 69 4 219 24 10.1159/000079151 1:CAS:528:DC%2BD2cXmsV2hs7s%3D 15205570 (Pubitemid 39140467)
35. M Miyaki C Sato K Sakai 2000 Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma Int J Cancer 85 4 518 22 10.1002/(SICI)1097- 0215(20000215)85:4<518::AID-IJC12>3.0.CO;2-7 1:CAS:528: DC%2BD3cXht1amtrs%3D 10699924 (Pubitemid 30075130)
36. K Bloom D Harrington 2004 Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy Am J Clin Pathol 121 620 30 10.1309/Y73U8X72B68TMGH5 15151201
37. HA Lehr TW Jacobs H Yaziji SJ Schnitt AM Gown 2001 Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis Am J Clin Pathol 115 814 22 10.1309/AJ84-50AK-1X1B-1Q4C 1:CAS:528:DC%2BD3MXksVyhsbY%3D 11392876 (Pubitemid 32476706)
38. E Tsiambas I Stavrakis AC Lazaris A Karameris E Patsouris 2007 Evaluation of epidermal growth factor receptor gene and chromosome 7 alterations in squamous cell carcinoma of the larynx, using chromogenic in situ hybridization on tissue microarrays J Laryngol Otol 121 563 570 10.1017/S0022215106002374 1:STN:280:DC%2BD2s3pvV2msQ%3D%3D 16882359 (Pubitemid 46800174)
39. E Tsiambas L Manaios K Papanikolopoulos 2008 Epidermal growth factor receptor, vascular endothelial growth factor and hypoxia inducible factor 1a simultaneous deregulation in hepatocellular carcinoma based on tissue microarrays and quantitative protein analysis J Hepatol Suppl 2 48 S206
40. RK Ramanathan CP Belani DA Singh 2006 Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial J Clin Oncol 24 401 10.1200/JCO.2005.03.6046 (Pubitemid 46630459)
41. L Liu Y Cao Ch Chen 2008 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumour cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 24 11851 11858 10.1158/0008-5472.CAN-06- 1377